University of Sussex
Transcript of University of Sussex
“Taking Samples”: Historicizing the
Biotech Narrative and the Formation of
Regulatory Practice (South Korea, and
Singapore, early 1960s-present)John DiMoia, Department
of History, NUS / Max Planck Institute for the History of Science,
2014-20161
Q: What makes a “Biotech” story? (vs US version / Genentech) •*The economic success
narrative (implicit)
•* The recent story (Hwang, post—1997) (or Biopolis, for Singapore)
•*JTC (SG), and state-driven (SK)
2
Looking at these two cases:
• Hoping to suggest much more humble, developmental origins / circumstances
• Hoping to suggest an earlier context for regulatory practice (even if not always a direct link for the biology)
3
The official / sanctioned story
• JTC (Jurong Town Corporation), Philip Yeo
• Strategic Investment since about 2000
• “liberal laws,” good governance, a space apart from Bush-era stem cell line limitations
11
Framing: The blastocysts story? / Human Reproduction—early to mid-1990s
• ART program at National University Hospital
• Establish protocols for handling, storing, working with tissues (embryos)
• Famous “stem-cell like” objects (now recognized as a precursor, even if not the isolation of HESC lines)
Fertilization and early embryology: Isolation and culture of inner cell mass cells from human blastocystsAriff Bongso1, Chui-Yee Fong, Soon-Chye Ng and Shan Ratnam
13
In summary
• Taking samples (practice, national scale)• Changing behaviors (consent, participation, storage and handling of tissues)
• Mobilization (mass campaigns)
• A context for later efforts, when the “real” biotech comes along in late 20th century, early 21st
14